Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) by Passweg, J. R. et al.
ARTICLE IN PRESS
Biol Blood Marrow Transplant 000 (2019) 16
Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgPostremission Consolidation by Autologous Hematopoietic Cell
Transplantation (HCT) for Acute Myeloid Leukemia in First Complete
Remission (CR) and Negative Implications for Subsequent Allogeneic
HCT in Second CR: A Study by the Acute Leukemia Working Party of the
European Society for Blood and Marrow Transplantation (EBMT)J.R. Passweg1,*, M. Labopin2, M. Christopeit3, J. Cornelissen4, T. Pabst5, G. Socie6, N. Russel7,
I. Yakoub-Agha8, D. Blaise9, T. Gedde-Dahl10, H. Labussiere-Wallet11, R Malladi12, E Forcade13,
S. Maury14, E. Polge15, F. Lanza16, N.C. Gorin2, M. Mohty2, A. Nagler17
1 Division of Hematology, University Hospital Basel, Basel, Switzerland
2 Department of Hematology and Cell Therapy, Institut National de la Sante et de la Recherche Medicale (INSERM) UMRs 938, Hopital Saint Antoine Assistance Publique-
Hopitaux de Paris, Paris Sorbonne University, Paris, France
3 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
4 Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands
5 Department of Medical Oncology, University Hospital, Bern, Switzerland
6 Department of Hematology-BMT, Hopital St. Louis, Paris France
7 Department of Haematology, Nottingham City Hospital, Nottingham University, Nottingham, UK
8 CHU de Lille, LIRIC, INSERM U995, universite de Lille, Lille, France
9 Programme de Transplantation & Therapie Cellulaire Centre de Recherche en Cancerologie de Marseille Institut Paoli Calmettes, Marseille, France
10 Department of Hematology, Oslo University Hospital, Rikshospitalet, and Institute for Clinical Medicine, University of Oslo, Oslo, Norway
11 Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Lyon, France
12 Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK
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After autologous hematopoietic cell transplantation (HCT) in the first complete remission (CR1), patients with
acute myeloid leukemia (AML) may relapse and undergo allogeneic HCT in the second complete remission (CR2).
The aim of this study was to analyze the outcome of allogeneic HCT performed in CR2 comparing patients with
prior consolidation by autologous HCT versus patients with chemotherapy consolidation. Included were 2619
adults with allogeneic HCT in CR2 from 2000 to 2017 with (n = 417) or without (n = 2202) prior autologous HCT.
Patient groups were not entirely comparable; patients with prior autologous HCT were younger, had less often a
favorable cytogenetic profile, had more commonly donors other than matched siblings, and more often received
reduced-intensity conditioning. In multivariate analysis, nonrelapse mortality risks in patients with prior autolo-
gous HCT were 1.34 (1.07 to 1.67; P = .01) after adjustment for age, cytogenetic risk, transplant year, donor, condi-
tioning intensity, sex matching, interval diagnosis-relapse, and relapse-allogeneic HCT as compared with
chemotherapy consolidation. Similarly, risks of events in leukemia-free survival and graft-versus-host disease,
relapse-free survival were higher with prior autologous HCT, 1.17 (1.01 to 1.35), P = .03 and 1.18 (1.03 to 1.35),
P = .02, respectively. Risk of death was also higher, 1.13 (0.97 to 1.32), P = .1, but this was not significant. Postre-
mission consolidation with autologous HCT for AML in CR1 increases toxicity of subsequent allogeneic HCT in CR2.
© 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.Keywords:
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During the past decades, autologous hematopoietic cell
transplantation (HCT) has been widely used as consolidation
treatment in patients with acute myeloid leukemia (AML) in
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(CR2) [1-11]. Over time, donors for allogeneic stem cell trans-
plantation have become available, and allogeneic HCT appears
to have in part replaced autologous HCT.
Autologous HCT was shown to reduce relapse rates by
approximately 10% and increase leukemia-free survival (LFS)
but not overall survival in a randomized clinical study [1]. Con-
solidation by autologous HCT is used more commonly in
patients with low- and intermediate-risk AML, whereas for
high-risk AML, allogeneic HCT is more commonly recom-
mended. Up to half of patients receiving consolidation by
autologous HCT in CR1 will relapse and will be candidates for
allogeneic HCT in CR2 [1]. Although observational registry
studies will not be able to answer whether a strategy of early
allogeneic HCT is better than consolidation by chemotherapy
or autologous HCT and allogeneic HCT in case of relapse, the
toxicity of allogeneic HCT in CR2 in patients having received
consolidation treatment by autologous HCT or by chemother-
apy can be quantified and compared.
This study compares mortality after allogeneic HCT in CR2
in patients with AML who have received consolidation treat-
ment in CR1 by autologous HCT versus those who have
received consolidation by chemotherapy only. A difference in
mortality may indicate added burden of toxicity by autologous
HCT consolidation in case later allogeneic HCT is required to
treat relapsed disease.PATIENTS ANDMETHODS
This is an observational study including adult patients (18 years)
with de novo AML (non-acute promyleocytic leukemia) registered with
the European Society for Blood and Marrow Transplantation (EBMT)
receiving an allogeneic HCT in CR2 between 2000 and 2017 and who
had received either chemotherapy consolidation (n = 2202) or consolida-
tion by autologous HCT (n = 417) in CR1. Included were patients in
whom the date of relapse was reported and whose donor was a matched
sibling, an unrelated donor, or a haploidentical donor.
The EBMT is a nonprofit scientific society representing more than
600 transplant centers, mostly located in Europe, that are required to
report all consecutive stem cell transplantations and follow-up data once
a year. Data are entered, managed, and maintained in a central database
with Internet access; each EBMT center is represented in this database.
Audits are routinely performed to determine the accuracy of the data.
Patients or their legal guardians provide informed consent authorizing
the use of their personal information for research purposes according to
the Declaration of Helsinki. The Review Board of the EBMT approved this
study.ENDPOINTS
The main outcome of this study was nonrelapse mortality
(NRM) of allogeneic HCT in CR2 comparing patients with prior
autologous HCT to patients with chemotherapy consolidation.
NRM was defined as death without evidence of relapse or pro-
gression. CR was understood as complete hematologic remis-
sion, and this was defined as less than 5% bone marrow blasts.
Relapse was defined as the presence of 5% or more bone mar-
row blasts after remission was obtained.
Secondary outcomes were overall survival (OS), defined as
time from allogeneic HCT in CR2 to death from any cause. LFS
was defined as time from allogeneic HCT in CR2 to relapse or
progression or death from any cause. Acute graft-versus-host
disease (GVHD) was graded according to the modified Seattle-
Glucksberg criteria [12] and chronic GVHD according to the
revised Seattle criteria [13]. GVHD-free, relapse-free survival
(GRFS) was defined using the EBMT definition for registry-
based analyses where the time to first event among the follow-
ing is recorded: severe grade III or IV acute GVHD, severe
chronic GVHD, relapse, and death [14].DEFINITIONS
Conditioning regimen was defined myeloablative condi-
tioning (MAC) when containing total body irradiation (TBI)
with a dose >6 Gray or a total dose of busulfan >8 mg/kg or
>6.4 mg/kg when administered orally or intravenously,
respectively. All other regimens were defined as reduced-
intensity conditioning (RIC) [15]. Cytogenetic abnormalities
were classified according to medical research council UK crite-
ria [16].
STATISTICS
Groups were compared using the Mann-Whitney U test for
continuous variables and chi-squared test for categorical varia-
bles. Cumulative incidence was used to estimate the endpoints
of NRM and relapse incidence to accommodate competing
risks [17,18]. Probabilities of OS, LFS, and GRFS were calculated
using the Kaplan-Meier method [19]. Univariate analyses were
done using the Gray test for cumulative incidence functions
and the log-rank test for OS, GRFS, and LFS. Continuous varia-
bles were entered as continuous covariates in multivariate
analyses. Cox proportional hazards models were run to adjust
for differences among groups [20,21], entering all variables dif-
fering significantly between the 2 groups. All variables differ-
ing significantly between the 2 groups or factors known to
influence outcomes were included in the Cox model: patient
age, year of transplant, time from diagnosis to relapse, and
time from relapse to allograft were included as continuous var-
iables. Other variables were cytogenetic risk group (favorable,
intermediate, adverse, or NA), donor type, conditioning inten-
sity, sex matching, Karnofsky performance score, and patient
cytomegalovirus serology. Probabilities of the respective sur-
vival times are reported at 2 years after allogeneic HCT. To test
for a center effect, we introduced a random effect or frailty for
each center into the model [22,23]. Results were expressed as
the hazard ratio with the 95% confidence interval%. All tests
were 2-sided. The type I error rate was fixed at 0.05 for the
determination of factors associated with time-to-event out-
comes. Statistical analyses were performed with SPSS 24.0
(SPSS, Inc, Chicago, IL) and R 3.4.0 (R Foundation for Statistical
Computing, Vienna, Austria).
RESULTS
This study included 2619 adults with de novo AML who
received their first allogeneic HCT in CR2 from 2000 to 2017.
In total, 417 patients had undergone autologous HCT as part of
the consolidation treatment in CR1 and had subsequently
relapsed, and 2202 patients had undergone consolidation
treatment by chemotherapy only. Patient, disease, and treat-
ment characteristics are shown in Table 1. Patients with prior
autologous HCT differed from patients with chemotherapy
consolidation in many ways. They were younger by 2.7 years,
had undergone transplantation earlier (median 2009 as com-
pared with 2010), less often had a favorable cytogenetic pro-
file, more commonly underwent transplantation with
alternative donors other than matched siblings, and more
often had RIC as compared with MAC conditioning. Patients
with prior autologous HCT had an interval to relapse that was
shorter by a median of 41 days from diagnosis of AML. Time
from CR2 to allogeneic HCT was comparable in both groups.
Conditioning for prior autologous HCT was by TBI in 50, by
busulfan in combination with cyclophosphamide in 168, with
melphalan in 56, with other drugs in 34, and by drug combina-
tions not containing busulfan in 23. The type of conditioning
for prior autologous HCT was unknown in 86; these had not
been reported as transplants to the EBMT.
Table 1
Patient Disease and Transplant Characteristics
Characteristic Chemotherapy Consolidation Autologous HCT Consolidation P Value
Number 2202 417
Age (IQR), yr 48.2 (36.9-58.4) 45.5 (36-55.5) .003
Year of transplant 2010 (2006-2014) 2009 (2005-2013) .002
Time to first relapse, d 406 (281-630) 365 (222-695) .03
Time relapse to allogeneic HCT, d 130 (15-361) 128 (29-363) NS
Genetic risk category, n (%) .001
Favorable 569 (29.0%) 55 (18.8%)
Intermediate 1244 (63.5%) 216 (73.7%)
Unfavorable 146 (7.5%) 22 (7.5%)
Karnofsky performance score, n (%) .92
<80 101 (5.1%) 20 (5.2%)
80 1888 (94.9%) 365 (94.8%)
Patient CMV serology, n (%) .38
Negative 785 (36.3%) 123 (33.9%)
Positive 1380 (63.7%) 240 (66.1%)
Donor, n (%) .0001
Matched sibling 763 (34.7%) 77 (18.5%)
Unrelated 1291 (58.6%) 301 (72.2%)
Haploidentical 148 (6.7%) 39 (9.4%)
Donor recipient sex mismatch, n (%) .22
Female into male 401 (18.3%) 65 (15.7%)
Other combinations 1792 (81.7%) 348 (84.3%)
Conditioning, n (%) .0001
Myeloablative 1227 (55.8%) 190 (46.1%)
Reduced intensity 973 (44.2%) 222 (53.9%)
In vivo T cell depletion, n (%) .08
Yes 1252 (57.3%) 230 (62.2%)
No 934 (42.7%) 140 (37.8%)
In vitro T cell depletion, n (%) 79 (3.6%) 23 (5.5%) .06
Stem cell source, n (%) .11
BM 451 (20.5%) 100 (24.0%)
PB 1751 (79.5%) 317 (76.0%)
IQR indicates interquartile range; NS, not significant; CMV, cytomegalovirus; BM, bone marrow; PB, peripheral blood.
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(NRM) and 2 (LFS). In univariate analysis, NRM was higher and
LFS lower by approximately 4% in patients with prior autolo-
gous HCT consolidation as compared with chemotherapy con-
solidation. Given the important differences among groups,
multivariate analysis adjusting for these differences, including
patient age, cytogenetic risk, year of transplant, donor type,
conditioning intensity, sex matching, the time interval from
diagnosis to relapse, and the time interval from relapse to allo-
geneic HCT into the model, is more reliable.Table 2
Univariate and Multivariate Outcomes
Characteristic Chemotherapy Consolidation Autologous
NRM (2 yr) 21.3 (19.6-23.1) 25.2 (21-29
Relapse (2 yr) 28.1 (26.1-30) 28.6 (24.1-3
OS (2 yr) 58.1 (55.9-60.2) 55.2 (50.2-6
LFS (2 yr) 50.6 (48.4-52.8) 46.2 (41.2-5
GRFS (2 yr) 39.7 (37.5-41.8) 35.7 (30.8-4
Acute GVHD II-IV (100 d) 25.6 (23.8-27.5) 23.7 (19.6-2
Chronic GVHD (2 y) 40.2 (37.9-42.4) 37.5 (32-43
MVA indicates multivariate analysis, NRM probability of NRM in the MVA this is hazar
* Baseline is chemotherapy consolidation with a relative risk of event of 1.00.Relative risks of NRM were 1.34 (1.07 to 1.67; P = .01) in
patients with prior autologous HCT versus chemotherapy con-
solidation. Similarly, LFS risks were 1.17 (1.01 to 1.35; P = .03),
GRFS risks were 1.18 (1.03 to 1.35, P = .02), and OS was 1.13
(0.974 to 1.32; P = .1) comparing the groups with prior autolo-
gous HCT to patients with chemotherapy consolidation. A sub-
group of patients with prior autologous HCT had a particularly
poor outcome; these patients had received conditioning by TBI
for autologous HCT (n = 50), contributing to higher mortality
of subsequent allogeneic HCT, which had been reported in aHCT Consolidation P Value MVA* P Value
.6) .008 1.32 (1.03-1.69) .03
3.2) NS 1.07 (0.85-1.34) .58
0.2) .02 1.19 (1.01-1.41) .04
1.2) .004 1.20 (1.02-1.41) .03
0.5) .02 1.18 (1.01-1.38) .03
8) .33 0.87 (0.66-1.13) .29
) .27 0.93 (0.73-1.19) .56
d rate.
Figure 1. Univariate NRM incidence for patients with prior autologous HCT consolidation versus chemotherapy consolidation.
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1.32 (1.03 to 1.69) comparing patients with prior autologous
HCT consolidation to patients without. When analyzing
patients with autologous HCT conditioning without TBI sepa-
rately from patients with TBI, the risk of NRM of the non-TBI
patients was 1.21 (0.957 to 1.54) as compared with patients
without autologous HCT. Conversely, NRM risks of allogeneic
HCT were highest in the patients with TBI conditioning for
autologous HCT (relative risk: 2.7 [1.67 to 4.37]). Causes of
death after allogeneic HCT in CR2 in both groups were domi-
nated by relapsed disease in 39.1% and 46.7%, GVHD in 16.4%
and 19.9%, and infectious disease in 26.8% and 19.4% when
comparing patients with autologous HCT consolidation to che-
motherapy consolidation in CR1. Sinusoidal obstruction syn-
drome of the liver was the cause of death in 2.7% versus 1.9%,
interstitial pneumonitis in 4.1% versus 2.7%, cardiac toxicity in
0.9% versus 0.7%, and secondary malignancy in 3.2% versus
1.7% of patients, respectively. The P value of comparing cause
of death was .28.
DISCUSSION
Use of autologous HCT for AML is not well standardized.
Some groups advocate this strategy as appropriate consolida-
tion treatment in patients with genetically low- or intermedi-
ate-risk AML. Use, particularly in CR1, shows a steep increase
over the 1990s, with a rapid drop after 2000, as reported to
the EBMT activity survey. Authors interpret the data as show-
ing a probable switch to allogeneic HCT consolidation at thetime when HLA high-resolution typing became available and
large numbers of unrelated donors were accessible for HCT,
rather than the result of comparative studies, of which only
relatively few have been published.
The best evidence for autologous HCT in CR1 comes from a
randomized clinical trial showing a reduced relapse rate by
approximately 10% with improved LFS but no significant dif-
ference in OS [1] published in 2011. This study had not found
an interaction between relapse risk reduction by autologous
HCT and genetic risk categories. Patients in CR1, even if in
genetic low- and intermediate-risk categories, would have a
risk of relapse of 40% to 50% even after consolidation by autol-
ogous HCT [1]. Relapsing patients would most commonly
undergo reinduction chemotherapy following consolidation in
CR2 by allogeneic HCT.
Previous studies from the acute leukemia working party
(ALWP) of the European Society for Blood and Marrow Trans-
plantation (EBMT) had compared the outcome of patients with
acute leukemia with a relapse after autologous HCT treated
with chemotherapy, a second autologous HCT, or an allogeneic
HCT [6,7]. In these studies with patients treated before 2000,
outcome was not significantly different after a second auto-
graft or an allogeneic HCT with OS of 42% § 6% and 32% § 5%,
respectively. Young age and interval from first autograft to the
second transplant >8 months and the absence of prior TBI had
a more favorable outcome. Outcome of patients treated with-
out a second transplant was very poor. A study published in
2013 with 302 patients undergoing an unrelated allogeneic
Figure 2. Univariate LFS probabilities for patients with prior autologous HCT consolidation versus chemotherapy consolidation.
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showed a LFS of 20% at 5 years. Results were better in patients
with a longer interval to second HCT, a high Karnofsky perfor-
mance score, and RIC [8]. These studies, as well as a study
recently published by the ALWP of the EBMT [10], looked at
the outcome of allogeneic HCT following relapse after autolo-
gous HCT and reported that patients with less aggressive dis-
ease and in a better state of health fared better. However,
these studies did not address whether prior autologous HCT
affected the toxicity of subsequent allogeneic HCT.
Here we provide evidence that toxicity measured as NRM is
increased after allogeneic HCT in CR2 if consolidation in CR1
had been by autologous HCT rather than chemotherapy alone.
However, differences are small (ie, approximately 4% by uni-
variate analysis), and it is not clear whether this difference is
driven by cumulative toxicity of higher doses of chemotherapy
or by other factors. The groups of patients with prior autolo-
gous HCT and chemotherapy consolidation differed in many
aspects, and groups were heterogeneous. In particular,
patients with prior autologous HCT had more commonly RIC
for allogeneic HCT in CR2, despite them being younger as com-
pared with the chemotherapy consolidation group. As this is
an observational study, we do not have control over treatment
choices and assume that RIC regimens were chosen more com-
monly to avoid toxicity considered to be higher, given prior
autologous HCT conditioning. Patients with prior autologous
HCT had more often intermediate-risk cytogenetics as com-
pared with the chemotherapy consolidation group, pointing
toward a (desired) selection bias. There were, however, nodifferences in relapse rates. We carefully adjusted for these dif-
ferences by multivariate analysis, particularly for conditioning
intensity, but other factors not measured or not appreciated
sufficiently may have an impact. For instance, we lack informa-
tion on the number of chemotherapy cycles to achieve CR1 as
well as the number of cycles to achieve CR2. In addition, there
are data missing on the conditioning regimen of autologous
HCT in a proportion of these patients. Patients with condition-
ing for autologous HCT by TBI fared particularly poorly, but
patients without TBI conditioning had higher NRM risks,
although this was only of borderline significance. Last, this
study is obviously agnostic to the benefit of autologous HCT in
CR1 (ie, we only analyzed patients who experienced a relapse
and achieved CR2). We also do not know about patients who
did not achieve a CR2 or patients who could not undergo an
allogeneic HCT in CR2 because of lack of donor or comorbid
conditions. Despite these limitations, this study shows that
patients receiving an allograft in CR2 may be at a slightly
higher risk of nonrelapse mortality after having received a
consolidation treatment by autologous HCT as compared with
chemotherapy consolidation.ACKNOWLEDGMENTS
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